|

Selinexor Clinical Trials

21 actively recruiting trials across 9 locations

Also known as: ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, Gemcitabine, KPT 330, KPT-330, KPT330, Nexpovio, S, SINE KPT-330, Selective Inhibitor of Nuclear Export KPT-330, XPOVIO, XPOVIO®, Xpovio, Xpovio, Nexpovio, xpo1 inhibitor

Other9 trials

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Phase 2
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Phase 2
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Phase 2
Second-line Immunotherapy for ES-SCLC
N/A
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Phase 1/2
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
Phase 1
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Phase 1/2
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3

Birmingham, Alabama3 trials

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Children's Hospital of Alabama

Phase 1/2
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

The University of Alabama at Birmingham

Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham - Main /ID# 261434

Phase 3

Los Angeles, California2 trials

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Children's Hospital of Los Angeles (Data Collection Only)

Phase 2
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Keck Medicine of USC Koreatown

Phase 2

Gilbert, Arizona1 trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Tucson, Arizona1 trial

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

UACC Arizona

Phase 2

West Hollywood, California1 trial

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Berenson Cancer Center

Phase 1

Coral Gables, Florida1 trial

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

University of Miami, Lennar Foundation Medical Center

Phase 2

Chicago, Illinois1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Lurie Children's Hospital of Chicago

Phase 1/2

Maywood, Illinois1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University Medical Center

Phase 2

Rochester, New York1 trial

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

University of Rochester

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.